SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis
SynAct Pharma AB ("SynAct") today announces that the company is making progress in the second and final dose level (100 mg) in part 1 in patients with a Rheumatoid Arthritis with high disease activity at clinics in Denmark and Sweden. The recruitment of part 1 of the clinical phase II study is expected to be completed within the next two months.CSO Thomas Jonassen says “The Covid-19 lockdown had major impact on the possibility to recruit patients to clinical trials, but we were fortunate to have the possibility to get some progress in the study during Covid-19 lockdown, not at least